Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Regeneron posted positive results with an overall survival (OS) benefit from the Phase 3 trial investigating its PD-1 inhibitor Libtayo (cemiplimab) monotherapy compared to chemotherapy in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
Roche is buying GenMark at a price of US$ 24.05 per share in an all-cash transaction, the companies announced Monday agreement with a total transaction value of approximately US$ 1.8 billion.
Ireland has temporarily halted using AstraZeneca’s Covid-19 vaccine Sunday, which came after a report from Norway of patients developing blood clots post inoculation.
Roche said Thursday that the global phase III randomised, double-blind, multicentre study of Actemra®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint.
Novartis said Tuesday its Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments.
Clinerion and Medexprim will set up a joint offering which allows access to de-identified, enriched, longitudinal data points derived from complex medical data sets, which combine electronic health records and their corresponding clinical images, to improve research and help patients receive better care.
AstraZeneca on Thursday said it expects its 2021 revenue to grow after its COVID-19 vaccine success topped previous estimates for fourth-quarter sales.
Abzena announced they have been chosen to work with Immunome Inc. to produce IMM-BCP-01 for clinical testing – an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.
WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.
CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment.